Rocket Pharmaceuticals (RCKT) Set to Release Earnings on Thursday

Rocket Pharmaceuticals (NASDAQ:RCKT) is expected to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Rocket Pharmaceuticals to announce earnings of ($0.39) per share and revenue of $0.20 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Rocket Pharmaceuticals (NASDAQ:RCKT) last announced its quarterly earnings data on Monday, August 10th. The biotechnology company reported $1.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.86 by $0.22. During the same quarter in the prior year, the firm earned ($0.62) earnings per share. On average, analysts expect Rocket Pharmaceuticals to post ($1.36) EPS for the current fiscal year and ($1.44) EPS for the next fiscal year.

Rocket Pharmaceuticals Price Performance

RCKT opened at $2.51 on Wednesday. The company has a fifty day moving average price of $2.92 and a two-hundred day moving average price of $3.44. The firm has a market capitalization of $275.55 million, a PE ratio of -14.76 and a beta of 0.51. Rocket Pharmaceuticals has a 52 week low of $2.16 and a 52 week high of $5.45. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.24 and a current ratio of 9.24.

Insiders Place Their Bets

In other news, General Counsel Martin Wilson sold 75,364 shares of the business’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $3.40, for a total value of $256,237.60. Following the completion of the transaction, the general counsel owned 598,489 shares of the company’s stock, valued at $2,034,862.60. The trade was a 11.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Christopher Stevens sold 36,658 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $3.50, for a total transaction of $128,303.00. Following the completion of the sale, the chief operating officer owned 505,784 shares of the company’s stock, valued at approximately $1,770,244. This represents a 6.76% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 125,977 shares of company stock worth $432,273. Insiders own 21.30% of the company’s stock.

Analysts Set New Price Targets

RCKT has been the subject of a number of analyst reports. Weiss Ratings cut Rocket Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. Wedbush reissued an “outperform” rating on shares of Rocket Pharmaceuticals in a research note on Wednesday, October 7th. Wall Street Zen raised Rocket Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, August 17th. Jefferies Financial Group restated a “hold” rating and set a $2.95 target price on shares of Rocket Pharmaceuticals in a report on Wednesday, October 7th. Finally, Needham & Company LLC upgraded Rocket Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.00 target price for the company in a research report on Wednesday, September 16th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Rocket Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $7.77.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare and devastating diseases. The company uses lentiviral and adeno-associated virus (AAV) technologies to address genetic disorders with significant unmet medical needs, including hematologic, metabolic, and cardiovascular conditions.

Rocket’s pipeline has included RP-L102 for Fanconi anemia, a rare inherited bone-marrow-failure disorder; RP-L201 for leukocyte adhesion deficiency-I, an immune disorder; and gene therapy programs targeting Danon disease and arrhythmogenic cardiomyopathy.